Last update Sept. 20, 2023

Zuranolone

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Zuranolone is a neuroactive steroid drug, GABA-A receptor modulator, used in the treatment of postpartum depression. Oral administration in a daily dose for 14 days. (FDA 2023).

It is excreted in breast milk in clinically insignificant amount. (FDA 2023)

May produce excessive sedation and confusion during administration (FDA 2023), so the mother should be monitored and accompanied.

Bed-sharing with the infant or remaining unattended while breastfeeding during administration of the product is not recommended.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Zuranolone in other languages or writings:

  • SAGE 217; SAGE-217; SAGE217 (Experimental code/s)
  • 1-[(3α, 5β)-3-hydroxy-3-methyl-20- oxo-19- norpregnan-21-yl]-1H-pyrazole-4-carbonitrile (Chemical name)
  • C25H35N3O2 (Molecular formula)
  • N06AX?? (ATC Code/s)

Group

Zuranolone belongs to this group or family:

Tradenames

Main tradenames from several countries containing Zuranolone in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 410 daltons
Protein Binding > 99.5 %
VD > 7 l/Kg
pKa 17.85 -
Tmax 5 - 6 hours
T½ 19.7 - 24.6 hours
Theoretical Dose 0.0013 mg/Kg/d
Relative Dose 0.36 %

References

  1. FDA. Zuranolone (Zurzuvae). Drug Summary. 2023 Consulted on Sept. 20, 2023 Full text (in our servers)

Total visits

957

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM